Ewer et al 1 have investigated the cardiotoxicity and reduction of the left ventricular ejection fraction (LVEF) associated with osimertinib. As osimertinib use increases, including for postoperative ...

Specifically, they are less effective at predicting cardiotoxicity, wherein a drug damages the heart. This is important because one-third of drugs withdrawn from testing are pulled due to ...

It highlights the fact that the elevated risk of trastuzumab-induced cardiotoxicity is closely associated with prior anthracycline exposure. In the absence of prior anthracycline exposure, the ...

Lab-grown "mini hearts" are being used to test new drugs researchers hope will protect breast cancer patients from heart failure ...

Patanjali's Cardiogrit Gold, a herbo-mineral Ayurvedic medicine, shows promise in mitigating chemotherapy-induced ...

DelveInsight's analysis underscores that as research continues and awareness grows, the cardiotoxicity market is poised for remarkable expansion and therapeutic innovation through 2032, supported by ...

Novel formulations of anthracycline analogs have been developed, but few have less cardiotoxicity or better cytotoxicity than that of doxorubicin. [109, 110] Those that do appear to be less ...

Cardiotoxicity of Trastuzumab in Clinical Practice Published July 5, 2007 N Engl J Med 2007;357: 94 - 95 DOI: 10.1056/NEJMc070065 ...

Cardiotoxicity presenting at least a year after the completion of anthracycline therapy is classified as late-onset cardiotoxicity and typically follows a chronic, progressive course. [38, 54 ...